SCHEMBL6070145

SCHEMBL6070145

CN1CCN(S(=O)(=O)c2c[c]ccc2Cl)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.55
POLB P06746 2/20 0.52
ATM Q13315 1/20 0.51
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
MAPT P10636 1/20 0.48
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4573045 0.84 LMNA (0.49) L3MBTL1POLBLMNAMAPTTSHR
SCHEMBL27734467 0.83 L3MBTL1 (0.46) L3MBTL1POLBATMKMT2ALMNA
SCHEMBL3279180 0.81 KMT2A (0.49) L3MBTL1POLBKMT2ALMNAMAPT
SCHEMBL15823601 0.81 ALDH1A1 (0.58) L3MBTL1POLBKMT2AMAPTTSHR
SCHEMBL2954361 0.77 POLB (0.67) L3MBTL1POLBATMKMT2ALMNA
SCHEMBL3568679 0.75 POLB (0.68) L3MBTL1POLBATMKMT2ALMNA
SCHEMBL1419404 0.73 POLB (0.65) L3MBTL1POLBATMKMT2ALMNA
SCHEMBL27952384 0.72 HSD11B1 (0.33) L3MBTL1LMNAALDH1A1
SCHEMBL3407131 0.72 L3MBTL1 (0.64) L3MBTL1POLBATMKMT2ALMNA
SCHEMBL3279540 0.71 ALDH1A1 (0.55) L3MBTL1POLBATMKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122565-B2 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT LLC (US) 2006-10-17 US disclosed
EP-1326853-B1 THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER LAMBERT CO (US) 2005-09-07 EP disclosed
CN-1639141-A Novel thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER LAMBERT CO (US) 2005-07-13 CN disclosed
EP-1326853-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS Warner-Lambert Company LLC (US) 2003-07-16 EP disclosed
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT COMPANY 2003-03-06 US disclosed
WO-2002028847-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors PDE3A, PDE3B, PDE7A L3MBTL1 4020/4885POLB 1113/4885ATM 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.